173 related articles for article (PubMed ID: 31489272)
1. Sudden-onset Hypoglycemia Following Fluid Replacement in a Patient with Dapagliflozin-induced Diabetic Ketoacidosis Without Prior Insulin Use: Case Report.
Elshimy G; Correa R
Cureus; 2019 Aug; 11(8):e5448. PubMed ID: 31489272
[TBL] [Abstract][Full Text] [Related]
2. SGLT-2 inhibitors and euglycemic diabetic ketoacidosis/diabetic ketoacidosis in FAERS: a pharmacovigilance assessment.
He Z; Lam K; Zhao W; Yang S; Li Y; Mo J; Gao S; Liang D; Qiu K; Huang M; Wu J
Acta Diabetol; 2023 Mar; 60(3):401-411. PubMed ID: 36576563
[TBL] [Abstract][Full Text] [Related]
3. Dapagliflozin-induced Late-onset Euglycemic Diabetic Ketoacidosis.
Iqbal I; Hamid M; Khan MAA; Kainat A; Tariq S
Cureus; 2019 Nov; 11(11):e6089. PubMed ID: 31857921
[TBL] [Abstract][Full Text] [Related]
4. Euglycemic diabetic ketoacidosis associated with sodium-glucose cotransporter-2 inhibitor use: a case report and review of the literature.
Diaz-Ramos A; Eilbert W; Marquez D
Int J Emerg Med; 2019 Sep; 12(1):27. PubMed ID: 31488052
[TBL] [Abstract][Full Text] [Related]
5. [Euglycemic Diabetic Ketoacidosis Caused by a Sodium-glucose Co-transporter (SGLT) 2 Inhibitor after Coronary Artery Bypass Grafting].
Kameda Y; Kato M; Inoue B; Yamazaki S; Sahara N; Aoki T; Nagashima Y; Nemoto N; Anzai H; Araki W; Kobayashi N
Kyobu Geka; 2019 May; 72(5):354-357. PubMed ID: 31268032
[TBL] [Abstract][Full Text] [Related]
6. A Literature Review of the Therapeutic Perspectives of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor-Induced Euglycemic Diabetic Ketoacidosis.
Patel K; Nair A
Cureus; 2022 Sep; 14(9):e29652. PubMed ID: 36320965
[TBL] [Abstract][Full Text] [Related]
7. Self-Induced Euglycemic Diabetic Ketoacidosis: When to Stop the Drip.
Zughaib MT; Patel K; Leka M; Affas S
Cureus; 2022 Jan; 14(1):e21768. PubMed ID: 35251838
[TBL] [Abstract][Full Text] [Related]
8. SGLT-2 Inhibitor-Associated Euglycemic Diabetic Ketoacidosis: A Case Report and a Literature Review.
Mahfooz RS; Khan MK; Al Hennawi H; Khedr A
Cureus; 2022 Jun; 14(6):e26267. PubMed ID: 35911365
[TBL] [Abstract][Full Text] [Related]
9. SGLT2 Inhibitors: A Systematic Review of Diabetic Ketoacidosis and Related Risk Factors in the Primary Literature.
Burke KR; Schumacher CA; Harpe SE
Pharmacotherapy; 2017 Feb; 37(2):187-194. PubMed ID: 27931088
[TBL] [Abstract][Full Text] [Related]
10. Late-Onset Euglycemic Diabetic Ketoacidosis in a Patient With Massive Stroke Requiring Decompressive Craniectomy: A Case Report.
Hussaini SA; Aziz A; Musa M; Alamin M; Danjuma M
Cureus; 2021 Oct; 13(10):e18629. PubMed ID: 34765377
[TBL] [Abstract][Full Text] [Related]
11. Combined SGLT1 and SGLT2 Inhibitors and Their Role in Diabetes Care.
Danne T; Biester T; Kordonouri O
Diabetes Technol Ther; 2018 Jun; 20(S2):S269-S277. PubMed ID: 29916741
[TBL] [Abstract][Full Text] [Related]
12. Euglycemic Diabetic Ketoacidosis in the Setting of SGLT2 Inhibitor Use and Hypertriglyceridemia: A Case Report and Review of Literature.
Gajjar K; Luthra P
Cureus; 2019 Apr; 11(4):e4384. PubMed ID: 31218148
[TBL] [Abstract][Full Text] [Related]
13. Sodium-glucose co-transporter-2 inhibitor-associated euglycemic diabetic ketoacidosis that prompted the diagnosis of fulminant type-1 diabetes: A case report.
Yasuma T; Okano Y; Tanaka S; Nishihama K; Eguchi K; Inoue C; Maki K; Uchida A; Uemura M; Suzuki T; D'Alessandro-Gabazza CN; Gabazza EC; Yano Y
World J Clin Cases; 2021 May; 9(13):3163-3169. PubMed ID: 33969104
[TBL] [Abstract][Full Text] [Related]
14. Diabetic Ketoacidosis in Patients with Type 2 Diabetes on Sodium-Glucose Cotransporter-2 Inhibitors - A Case Series.
Sharma PV; Jobanputra YB; Lewin K; Bagatell S; Lichtstein DM
Rev Recent Clin Trials; 2018; 13(2):156-160. PubMed ID: 29542418
[TBL] [Abstract][Full Text] [Related]
15. EUGLYCEMIC DIABETIC KETOACIDOSIS (EDKA) IN A PATIENT RECEIVING DAPAGLIFLOZIN.
Sethi SM; Vohra M; Ali SA
Acta Endocrinol (Buchar); 2021; 17(2):266-269. PubMed ID: 34925578
[TBL] [Abstract][Full Text] [Related]
16. Dapagliflozin as an Adjunct Therapy to Insulin in Patients with Type 1 Diabetes Mellitus: Efficacy and Safety of this Combination.
Jendle JH; Ampudia-Blasco FJ; Füchtenbusch M; Pozzilli P
touchREV Endocrinol; 2021 Apr; 17(1):12-20. PubMed ID: 35118442
[TBL] [Abstract][Full Text] [Related]
17. SGLT2 Inhibitor-associated Diabetic Ketoacidosis: Clinical Review and Recommendations for Prevention and Diagnosis.
Goldenberg RM; Berard LD; Cheng AYY; Gilbert JD; Verma S; Woo VC; Yale JF
Clin Ther; 2016 Dec; 38(12):2654-2664.e1. PubMed ID: 28003053
[TBL] [Abstract][Full Text] [Related]
18. Tubular Injury Causing Protracted Glycosuria Following Withdrawal of a Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor: A Possible Role in the Development of Protracted Hypoglycemia and Ketoacidosis.
Hashi R; Fujiki N; Yagi T
Tohoku J Exp Med; 2021 Dec; 255(4):291-296. PubMed ID: 34911880
[TBL] [Abstract][Full Text] [Related]
19. Dapagliflozin-Associated Euglycemic Diabetic Ketoacidosis Presenting With Severe Abdominal Pain Mimicking Acute Peritonitis.
Wang Q; Wu K; Luo X; Dong X; Liu W; Tang Z; Zhang B
Cureus; 2022 Feb; 14(2):e22229. PubMed ID: 35340523
[TBL] [Abstract][Full Text] [Related]
20. Euglycemic Diabetic Ketoacidosis Presenting as Hypoglycemia in a Patient With Type 2 Diabetes and Von Gierke's Disease.
Tito E; Ramaswami A; Milbocker R; Edmond D
Cureus; 2024 Jan; 16(1):e52104. PubMed ID: 38344605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
